IRCT20200427047221N1 IRCT 2021-04-19 Zanjan University of Medical Sciences Memantine versus pelacebo as an adjunct in the treatment of children with Attention Deficit Hyperactivity Disorder: a double-blind randomized, placebo-controlled study Memantine versus pelacebo as an adjunct in the treatment of children with Attention Deficit Hyperactivity Disorder: a double-blind randomized, placebo-controlled study 2020-06-04 anticipated 200 Complete https://irct.ir/trial/47671 interventional Randomization: Not randomized, Blinding: Double blinded, Placebo: Used, Assignment: Factorial, Purpose: Treatment, Blinding description: a double-blind randomized, placebo-controlled study. 2-3 Attention Deficit Hyperactivity Disorder. Intervention 1: Intervention group:The amount of prescription methylphenidate in the group receiving memantine is at least 10 mg and at most 50 mg, and the amount of prescription memantine in the group receiving memantine is at least 2.5 mg and at most 5 mg. Intervention 2: Control group:The prescription drug methylphenidate in the placebo group is at least 10 mg and at most 50 mg. Yes - There is a plan to make this available What will be shared: full content When: 6 month after publication To whom: university researchers Conditions: same subject Where to obtain: seyd yaser mousavi nodoushan How to obtain: by mailing to researcher Comments: by mailing to researcher